SECsense Logo

Ascendis Pharma A/S Issues Warrant Grants: February 2025 Form 6-K Highlights

$ASND
Form 6-K
Filed on: 2025-02-12
Source
Ascendis Pharma A/S Issues Warrant Grants: February 2025 Form 6-K Highlights

Here are the key insights extracted from the financial report provided:

  1. Company Information:
  • Name: Ascendis Pharma A/S
  • Address: Tuborg Boulevard 12, DK-2900 Hellerup, Denmark
  • Commission File Number: 001-36815
  1. Report Type:
  • This is a Form 6-K, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934.
  1. Date of Filing:
  • The report is dated February 12, 2025, with information pertaining to the month of February 2025.
  1. Warrant Grants:
  • On February 11, 2025, the board of directors granted 31,040 warrants to certain employees.
  • Each warrant allows the holder to subscribe for one ordinary share of the company at an exercise price of $119.51 per share.
  • The exercise price reflects the closing price of the American Depositary Shares (ADS) on the date of the grant.
  • Vesting Schedule:
    • 25% of the warrants will vest one year from the grant date.
    • The remaining 75% will vest at a rate of 1/36th per month starting one year after the grant, contingent on continued service.
    • Early vesting may occur upon certain exit events.
  1. Future Availability:
  • After the grant of these warrants, there are 1,946,973 warrants available for future grants under the company's Articles of Association.
  1. Incorporation by Reference:
  • The report states that it shall be incorporated by reference into several registration statements on Form S-8 and Form F-3 related to Ascendis Pharma A/S.
  1. Signatory Information:
  • The report is signed by Michael Wolff Jensen, the Executive Vice President and Chief Legal Officer of the company.

These points summarize the essential information and implications from the financial report, specifically regarding the warrant grants and general company details.